Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

36.42CHF
19 Jul 2019
Change (% chg)

CHF-0.08 (-0.22%)
Prev Close
CHF36.50
Open
CHF36.70
Day's High
CHF37.40
Day's Low
CHF35.84
Volume
70,422
Avg. Vol
46,729
52-wk High
CHF69.60
52-wk Low
CHF33.46

Latest Key Developments (Source: Significant Developments)

Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer
Monday, 1 Jul 2019 

July 1 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA EXTENDS PHASE 2 STUDY WITH DERAZANTINIB IN INTRAHEPATIC BILE DUCT CANCER (ICCA) TO INCLUDE PATIENTS WITH FGFR2 GENE MUTATIONS OR AMPLIFICATIONS.TOPLINE DATA FOR COHORT OF FGFR2 FUSION-POSITIVE PATIENTS ARE EXPECTED TO BE AVAILABLE AROUND MID-2020.  Full Article

Basilea Says Adesh Kaul Appointed CFO
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Basilea Pharmaceutica AG ::BASILEA ANNOUNCES CHANGE IN THE MANAGEMENT COMMITTEE - ADESH KAUL APPOINTED CFO.KAUL NEW CHIEF FINANCIAL OFFICER (CFO) AS OF APRIL 10, 2019.HE WILL SUCCEED DONATO SPOTA, WHO WILL CONTINUE IN HIS ROLE UNTIL ANNUAL GENERAL MEETING ON APRIL 10, 2019.  Full Article

Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Basilea Pharmaceutica Ag ::BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER.BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER.EXPECTS TO START A BIOMARKER-DRIVEN MULTI-COHORT PHASE 1/2 STUDY MID-2019.BASILEA WILL BE SPONSOR OF STUDY AND ROCHE WILL PROVIDE CLINICAL SUPPLY OF ATEZOLIZUMAB FOR STUDY.  Full Article

Basilea: Positive Interim Results From Registrational Phase 2 Study With Derazantinib
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Basilea Pharmaceutica AG ::BASILEA REPORTS POSITIVE INTERIM RESULTS FROM REGISTRATIONAL PHASE 2 STUDY WITH ONCOLOGY DRUG CANDIDATE DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA).21% OBJECTIVE RESPONSE RATE WITH SIX CONFIRMED PARTIAL RESPONSES FROM 29 EVALUABLE PATIENTS.83% DISEASE CONTROL RATE.  Full Article

Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib
Tuesday, 17 Apr 2018 

April 17 (Reuters) - ArQule Inc ::ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA.ARQULE INC - UNDER TERMS OF AGREEMENT, ARQULE WILL RECEIVE AN UPFRONT PAYMENT OF $10 MILLION.ARQULE INC - ARQULE ELIGIBLE TO RECEIVE UP TO $336 MILLION INCLUDING UPFRONT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.ARQULE - UNDER CERTAIN CIRCUMSTANCES, CO MAY HAVE OPPORTUNITY TO PROMOTE DERAZANTINIB IN U.S. DIRECTLY.ARQULE - ALSO ENTITLED TO RECEIVE STAGGERED SINGLE-DIGIT TO DOUBLE-DIGIT ROYALTIES ON NET SALES UPON COMMERCIALIZATION.ARQULE - BASILEA WILL BE RESPONSIBLE FOR ALL COSTS AND EXPENSES OF DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION IN ITS TERRITORY.  Full Article

Basilea Announces Completion Of License Agreement Extension With Pfizer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Basilea Pharmaceutica AG ::BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC.  Full Article

Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Basilea Pharmaceutica Ag ::‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​.‍BASILEA EXPECTS TO COMPLETE PHASE 1 PATIENT RECRUITMENT INTO SEPARATE GLIOBLASTOMA ARM OF ORAL STUDY IN FIRST HALF OF 2018​.  Full Article

Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB).  Full Article

Basilea Extends Existing License Agreement With Pfizer For Cresemba
Friday, 1 Dec 2017 

Dec 1 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER <<>> FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC.BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED.ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES.WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.FOR FY EXPECTS A REDUCED OPERATING LOSS OF APPROXIMATELY CHF 1 MILLION ON AVERAGE PER MONTH.FOR FY SEES LOWER OPERATING EXPENSES.  Full Article

Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - BASILEA PHARMACEUTICA AG ::‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​.  Full Article

Swiss stocks - Factors to watch on July 1

ZURICH/BERLIN, July 1 The Swiss blue-chip SMI was seen opening 0.7 percent higher at 9,969 points on Monday, according to premarket indications by bank Julius Baer .